The Bright Side

AI-Driven Cancer Biomarker Discovery Improves Patient Outcomes by 15% Cancer treatment has long been a process of educated guesswork—oncologists prescribe therapies based on tumor type and stage, then wait to see if patients respond. But AstraZeneca and Tempus AI's Predictive Biomarker Modeling Framework is changing that calculus,

Breakthrough Cancer Immunotherapy Shows 50% Response Rate in Advanced Sarcomas For patients with advanced soft tissue sarcomas, the statistics have been grim: second-line treatments typically show less than 5% response rates, and median survival often measures in months. But Iovance Biotherapeutics has announced results that could rewrite these outcomes, with